Fierce Pharma

MAY 13, 2024

Of all the allegations thrown at WuXi AppTec during an ongoing U.S. client's data to Beijing without consent, WuXi AppTec is again rebutting claims of its ties with Chinese authorities. Facing potential sanctions from the Department of Defense and a recent allegation that it had transferred a U.S.

247

247

Fierce Pharma

MARCH 28, 2024

intelligence officials reportedly flagged an unauthorized transfer of a customer's data by WuXi AppTec to Chinese authorities. AstraZeneca is working to separate its supply chains for the U.S. And more.

Pharma 130

Pharma Marketing 130

pharmaphorum

MARCH 29, 2024

Report claims US intelligence services advised the authors of the BIOSECURE Act that WuXi AppTec shared confidential data on US clients with the Chinese government

Government 81

Government 81

European Pharmaceutical Review

NOVEMBER 6, 2023

Advancements in biotechnology, pharmaceutical research, and biomanufacturing processes are key factors in driving the market, the author acknowledged. This is due to an increased production of antibodies and biologics drugs which require mammalian cells, the author explained. Sigma-Aldrich (Merck Group) and WuXi Biologics.

Pharmaceutical research 84

Pharmaceutical research Marketing Government Pharmaceutical 84

European Pharmaceutical Review

MARCH 27, 2024

For example, advanced instruments facilitate faster turnaround, increase reliability of test results and also offer benefit in terms of reducing human error, the authors shared. During a market recession, companies put less investment in R&D and consequently, this potentially slows the production of drugs, the authors shared.

Safety 68

Safety Marketing Food and Drug Administration Pharmaceutical 68

European Pharmaceutical Review

JANUARY 22, 2024

percent, the authors stated. The heightened and increasing demand for biopharmaceutical medicines has resulted in greater demand for E&L testing in drug safety, such as when mitigating cross-contamination risks” As part of this development, the authors noted that this has driven the growth of single-use systems.

Marketing 52

Marketing Safety Medicine Pharmaceutical 52

European Pharmaceutical Review

APRIL 3, 2024

This is due to these companies looking to meet to the varied needs of pharmaceutical developers, according to the authors. The report noted that there has been “considerable” merger and acquisition activity in recent years within the pharmaceutical contract manufacturing market.

Manufacturing 52

Manufacturing Pharmaceutical Marketing 52